Announcements Trials

Browse Landscape

Phase

Status

Withdrawn 1 Unknown 1 Completed 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Prostatic Neoplasms 32 Precursor Cell Lymphoblastic Leukemia-Lymphoma 2 Neoplasm Metastasis 2 Lymphoma, Non-Hodgkin 2 Lymphoma, Mantle-Cell 2 Lymphoma, Large-Cell, Immunoblastic 2 Lymphoma, Large B-Cell, Diffuse 2 Lymphoma, Follicular 2 Lymphoma, B-Cell, Marginal Zone 2 Lymphoma 2 Leukemia, Lymphocytic, Chronic, B-Cell 2 Burkitt Lymphoma 2 Thromboembolism 1 Sarcoma 1 Prostate Adenocarcinoma 1 Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1 Leukemia, Myeloid, Acute 1 Leukemia 1 Kidney Neoplasms 1 Hodgkin Disease 1 Fibrosarcoma 1 Carcinoma, Renal Cell 1 Breast Neoplasms 1

Interventions

Trastuzumab 351 Paclitaxel 334 Cyclophosphamide 315 Docetaxel 292 Capecitabine 181 Doxorubicin 180 Letrozole 165 Tamoxifen 145 Bevacizumab 124 Fulvestrant 118 Carboplatin 118 exemestane 111 Lapatinib 111 Anastrozole 111 Radiotherapy 105 Epirubicin 104 Gemcitabine 97 palbociclib 83 Exercise 78 Vinorelbine 77 Fluorouracil 77 Surveys and Questionnaires 71 pertuzumab 68 Filgrastim 64 Albumin-Bound Paclitaxel 64 Magnetic Resonance Spectroscopy 56 eribulin 55 Everolimus 52 Blood Specimen Collection 51 Zoledronic Acid 50

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Completed × Breast Neoplasms × Estramustine × Clear all

NCT02866955 2020-03-09

EFESE

Institut de Cancérologie de Lorraine

Phase 2 Completed

Breast Neoplasms, Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon ⚡